Tribute Pharmaceuticals Canada Inc. (TBUFF) 0.7600 $TBUFF
Tribute Pharmaceuticals to Participate at Laurentian Bank Securities Annual Investor Conference
Marketwired - Thu Apr 02, 8:16AM CDT
Tribute Pharmaceuticals Canada Inc. ("Tribute" or the "Company"
(TSX VENTURE: TRX) (OTCQX: TBUFF), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced that Mr. Rob Harris, its President and Chief Executive Officer will participate in a Specialty Pharmaceutical Healthcare Panel Discussion to be held on Thursday, April 9, 2015 at 1:35 PM ET at the Laurentian Bank Securities 2nd Annual Investor Conference in Montreal. Mr. Scott Langille, Tribute's Chief Financial Officer will also attend the conference.
TRX.VN: 0.980 (+0.090)
Tribute Raises US$2.7 Million Through the Exercise of Warrants
Marketwired - Thu Mar 19, 5:48PM CDT
Tribute Pharmaceuticals Canada Inc. (OTCQX: TBUFF)(TSX VENTURE: TRX) ("Tribute" or the "Company", a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the United States, today announced that holders of 5,431,250 or 90.1% of the Series A Warrants issued in connection with the Company's 2013 unit financing were exercised prior to their expiry resulting in proceeds to the Company of US$2,715,625.
TRX.VN: 0.980 (+0.090)
Tribute Pharmaceuticals Canada's (TBUFF) CEO Rob Harris on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Mar 03, 2:00PM CST
Tribute Pharmaceuticals Announces Strong 2014 Fourth Quarter and Year End Results
Marketwired - Tue Mar 03, 6:01AM CST
Tribute Pharmaceuticals Canada Inc. (TSX VENTURE: TRX)(OTCQX: TBUFF) ("Tribute" or the "Company", a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced its operational and financial results for the fourth quarter and year ended December 31, 2014. Unless otherwise indicated, all dollar amounts included herein are stated in Canadian dollars.
TRX.VN: 0.980 (+0.090)
Tribute Pharmaceuticals to Host Fourth Quarter and Fiscal Year 2014 Earnings Conference Call and Webcast Live on Tuesday, March 3, 2015
ACCESSWIRE - Mon Mar 02, 3:07PM CST
MILTON, ON / ACCESSWIRE / March 2, 2015 / Tribute Pharmaceuticals Canada Inc. (OTCQX: TBUFF) (TSX Venture: TRX) will host a conference call and live webcast to discuss the results of the fourth quarter and fiscal year 2014, to be held Tuesday, March 3, 2015 at 9:00 AM Eastern Time.
TRX.VN: 0.980 (+0.090)
Tribute Pharmaceuticals Board Members and Management Exercise Series A Warrants
Marketwired - Mon Mar 02, 8:54AM CST
Tribute Pharmaceuticals Canada Inc. (OTCQX: TBUFF) (TSX VENTURE: TRX) ("Tribute" or the "Company", a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the United States, today announced that 100% of the participants in Tranche I of the Company's February/March 2013 private placement of units, which included a majority of the Company's officers and directors, have exercised the Series A Warrants (as defined below) acquired by them in such financing prior to their expiration. A total of 4,218,750 Series A Warrants were exercised and an equal amount of common shares of the Company were issued, for an aggregate of US$2,109,375 in proceeds.
TRX.VN: 0.980 (+0.090)
Bloom Burton's David Martin Zeroes In On Under-The-Radar Biotech
Life Sciences Report - Seeking Alpha - Fri Feb 13, 9:24AM CST
Biotechnology indices have been on a rapid ascent for three years, and 2015 appears to be off to the races as well. Bloom Burton & Co.'s David Martin has taken his seat in the grandstands, betting on specialty pharma and biotech companies based...
AUPH: 4.17 (-0.06), TRIL: 28.73 (-0.36)
Tribute Pharmaceuticals Engages BND Projects Inc. as Investor Relations Service Provider and Grants Options to Certain Officers and Directors
Marketwired - Thu Jan 29, 3:14PM CST
Tribute Pharmaceuticals Canada Inc. (OTCQB: TBUFF)(TSX VENTURE: TRX) ("Tribute" or the "Company", a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the US, today announced that it has retained BND Projects Inc. ("BND" to provide it with investor relations services. The services to be provided by BND include (i) introducing the Company to the Canadian investment community, (ii) updating the investor base on a regular basis about the Company's fundamentals and goals and milestones, (iii) organizing investor road shows for the Company's management and (iv) assisting with the preparation of corporate communications and presentations.
TRX.VN: 0.980 (+0.090)
Tribute Pharmaceuticals Provides Update of 2014 Revenues; Anticipates Fourth Quarter Revenue Growth in Excess of 60% and Full Year Revenue Growth of Greater Than 20%
Marketwired - Tue Jan 27, 7:31AM CST
Tribute Pharmaceuticals Canada Inc. (OTCQX: TBUFF)(TSX VENTURE: TRX) ("Tribute" or the "Company", a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the US, today provided an interim update on its anticipated fourth quarter performance and total fiscal 2014 performance as follows:
TRX.VN: 0.980 (+0.090)
Tribute Pharma Q3 Update: Q4 Slated For Increase In Revenues
Anita Dushyanth - at Seeking Alpha - Thu Nov 13, 12:51PM CST
Tribute Pharmaceuticals Reports Double Digit Revenue Growth in Third Quarter 2014
Marketwire Canada - Mon Nov 10, 1:03PM CST
Tribute Pharmaceuticals Canada Inc. (OTCQX:TBUFF) (TSX VENTURE:TRX) ("Tribute" or the "Company", a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the US, today announced financial results for its third quarter ending September 30, 2014. In this press release, all dollar amounts are expressed in Canadian currency - unless otherwise noted - and results are reported in accordance with United States generally accepted accounting principles (U.S. GAAP).
TRX.VN: 0.980 (+0.090), NVS: 103.58 (+1.01)
Tribute Pharmaceuticals Canada EPS of C$0.03
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 9:52AM CST
Tribute Pharmaceuticals to Participate at Laurentian Bank Securities Annual Investor Conference
Marketwired - Thu Apr 02, 8:16AM CDT
Tribute Pharmaceuticals Canada Inc. ("Tribute" or the "Company"
(TSX VENTURE: TRX) (OTCQX: TBUFF), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced that Mr. Rob Harris, its President and Chief Executive Officer will participate in a Specialty Pharmaceutical Healthcare Panel Discussion to be held on Thursday, April 9, 2015 at 1:35 PM ET at the Laurentian Bank Securities 2nd Annual Investor Conference in Montreal. Mr. Scott Langille, Tribute's Chief Financial Officer will also attend the conference. TRX.VN: 0.980 (+0.090)
Tribute Raises US$2.7 Million Through the Exercise of Warrants
Marketwired - Thu Mar 19, 5:48PM CDT
Tribute Pharmaceuticals Canada Inc. (OTCQX: TBUFF)(TSX VENTURE: TRX) ("Tribute" or the "Company"
, a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the United States, today announced that holders of 5,431,250 or 90.1% of the Series A Warrants issued in connection with the Company's 2013 unit financing were exercised prior to their expiry resulting in proceeds to the Company of US$2,715,625. TRX.VN: 0.980 (+0.090)
Tribute Pharmaceuticals Canada's (TBUFF) CEO Rob Harris on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Mar 03, 2:00PM CST
Tribute Pharmaceuticals Announces Strong 2014 Fourth Quarter and Year End Results
Marketwired - Tue Mar 03, 6:01AM CST
Tribute Pharmaceuticals Canada Inc. (TSX VENTURE: TRX)(OTCQX: TBUFF) ("Tribute" or the "Company"
, a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced its operational and financial results for the fourth quarter and year ended December 31, 2014. Unless otherwise indicated, all dollar amounts included herein are stated in Canadian dollars. TRX.VN: 0.980 (+0.090)
Tribute Pharmaceuticals to Host Fourth Quarter and Fiscal Year 2014 Earnings Conference Call and Webcast Live on Tuesday, March 3, 2015
ACCESSWIRE - Mon Mar 02, 3:07PM CST
MILTON, ON / ACCESSWIRE / March 2, 2015 / Tribute Pharmaceuticals Canada Inc. (OTCQX: TBUFF) (TSX Venture: TRX) will host a conference call and live webcast to discuss the results of the fourth quarter and fiscal year 2014, to be held Tuesday, March 3, 2015 at 9:00 AM Eastern Time.
TRX.VN: 0.980 (+0.090)
Tribute Pharmaceuticals Board Members and Management Exercise Series A Warrants
Marketwired - Mon Mar 02, 8:54AM CST
Tribute Pharmaceuticals Canada Inc. (OTCQX: TBUFF) (TSX VENTURE: TRX) ("Tribute" or the "Company"
, a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the United States, today announced that 100% of the participants in Tranche I of the Company's February/March 2013 private placement of units, which included a majority of the Company's officers and directors, have exercised the Series A Warrants (as defined below) acquired by them in such financing prior to their expiration. A total of 4,218,750 Series A Warrants were exercised and an equal amount of common shares of the Company were issued, for an aggregate of US$2,109,375 in proceeds. TRX.VN: 0.980 (+0.090)
Bloom Burton's David Martin Zeroes In On Under-The-Radar Biotech
Life Sciences Report - Seeking Alpha - Fri Feb 13, 9:24AM CST
Biotechnology indices have been on a rapid ascent for three years, and 2015 appears to be off to the races as well. Bloom Burton & Co.'s David Martin has taken his seat in the grandstands, betting on specialty pharma and biotech companies based...
AUPH: 4.17 (-0.06), TRIL: 28.73 (-0.36)
Tribute Pharmaceuticals Engages BND Projects Inc. as Investor Relations Service Provider and Grants Options to Certain Officers and Directors
Marketwired - Thu Jan 29, 3:14PM CST
Tribute Pharmaceuticals Canada Inc. (OTCQB: TBUFF)(TSX VENTURE: TRX) ("Tribute" or the "Company"
, a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the US, today announced that it has retained BND Projects Inc. ("BND" to provide it with investor relations services. The services to be provided by BND include (i) introducing the Company to the Canadian investment community, (ii) updating the investor base on a regular basis about the Company's fundamentals and goals and milestones, (iii) organizing investor road shows for the Company's management and (iv) assisting with the preparation of corporate communications and presentations. TRX.VN: 0.980 (+0.090)
Tribute Pharmaceuticals Provides Update of 2014 Revenues; Anticipates Fourth Quarter Revenue Growth in Excess of 60% and Full Year Revenue Growth of Greater Than 20%
Marketwired - Tue Jan 27, 7:31AM CST
Tribute Pharmaceuticals Canada Inc. (OTCQX: TBUFF)(TSX VENTURE: TRX) ("Tribute" or the "Company"
, a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the US, today provided an interim update on its anticipated fourth quarter performance and total fiscal 2014 performance as follows: TRX.VN: 0.980 (+0.090)
Tribute Pharma Q3 Update: Q4 Slated For Increase In Revenues
Anita Dushyanth - at Seeking Alpha - Thu Nov 13, 12:51PM CST
Tribute Pharmaceuticals Reports Double Digit Revenue Growth in Third Quarter 2014
Marketwire Canada - Mon Nov 10, 1:03PM CST
Tribute Pharmaceuticals Canada Inc. (OTCQX:TBUFF) (TSX VENTURE:TRX) ("Tribute" or the "Company"
, a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the US, today announced financial results for its third quarter ending September 30, 2014. In this press release, all dollar amounts are expressed in Canadian currency - unless otherwise noted - and results are reported in accordance with United States generally accepted accounting principles (U.S. GAAP). TRX.VN: 0.980 (+0.090), NVS: 103.58 (+1.01)
Tribute Pharmaceuticals Canada EPS of C$0.03
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 9:52AM CST
